Ionis, AstraZeneca deal

AstraZeneca exercised an option under a 2012 deal to license exclusive, worldwide rights to develop and commercialize IONIS-KRAS-2.5Rx (AZD4785) from Ionis. The antisense candidate targeting K-Ras (KR...